BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, Rigopoulou EI, Dalekos GN. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol. 2008;28:501-511. [PMID: 18551357 DOI: 10.1007/s10875-008-9211-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Brusch A. The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome. Antibodies (Basel) 2016;5:E16. [PMID: 31557997 DOI: 10.3390/antib5020016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, Rigopoulou EI, Dalekos GN. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. Clinica Chimica Acta 2010;411:411-5. [DOI: 10.1016/j.cca.2009.12.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
3 Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, Dalekos GN, Rigopoulou EI. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. Eur J Intern Med 2017;42:81-8. [PMID: 28535947 DOI: 10.1016/j.ejim.2017.05.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
4 Cabrera-Marante O, Rodríguez de Frías E, Serrano M, Lozano Morillo F, Naranjo L, Gil-Etayo FJ, Paz-Artal E, Pleguezuelo DE, Serrano A. The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. Int J Mol Sci 2020;21:E8972. [PMID: 33255963 DOI: 10.3390/ijms21238972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Marzorati S, Invernizzi P, Lleo A. Making Sense of Autoantibodies in Cholestatic Liver Diseases. Clinics in Liver Disease 2016;20:33-46. [DOI: 10.1016/j.cld.2015.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
6 Gatselis NK, Zachou K, Dalekos GN. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. Gastroenterol Res Pract 2010;2010:121620. [PMID: 20706542 DOI: 10.1155/2010/121620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Andreoli L, Fredi M, Nalli C, Piantoni S, Reggia R, Dall'Ara F, Franceschini F, Tincani A. Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. Curr Rheumatol Rep 2013;15:343. [PMID: 23754504 DOI: 10.1007/s11926-013-0343-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
8 Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015; 21(1): 60-83 [PMID: 25574080 DOI: 10.3748/wjg.v21.i1.60] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
9 Sipeki N, Davida L, Palyu E, Altorjay I, Harsfalvi J, Antal Szalmas P, Szabo Z, Veres G, Shums Z, Norman GL, Lakatos PL, Papp M. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease. World J Gastroenterol 2015; 21(22): 6952-6964 [PMID: 26078573 DOI: 10.3748/wjg.v21.i22.6952] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
10 Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 2018;27:572-83. [PMID: 28945149 DOI: 10.1177/0961203317731532] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 12.0] [Reference Citation Analysis]
11 Martínez-Flores JA, Serrano M, Alfaro J, Mora S, Paz-Artal E, Morales JM, Serrano A. Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Anal Chem 2013;85:12093-8. [PMID: 24245938 DOI: 10.1021/ac403194t] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
12 Ambrosino P, Lupoli R, Tarantino P, Di Minno A, Tarantino L, Di Minno MND. Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis. Digestive and Liver Disease 2015;47:478-87. [DOI: 10.1016/j.dld.2015.03.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
13 Rigopoulou EI, Zachou K, Gatselis NK, Papadamou G, Koukoulis GK, Dalekos GN. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. World J Hepatol 2013; 5(10): 577-583 [PMID: 24179617 DOI: 10.4254/wjh.v5.i10.577] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
14 Gatselis NK, Zachou K, Norman GL, Tzellas G, Speletas M, Gabeta S, Germenis A, Koukoulis GK, Dalekos GN. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta. 2012;413:1683-1688. [PMID: 22643316 DOI: 10.1016/j.cca.2012.05.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
15 Azarsiz E, Eman G, Akarcan SE, Severcan EU, Karaca N, Aksu G, Kutukculer N. Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders. Indian J Clin Biochem 2019;34:95-100. [PMID: 30728679 DOI: 10.1007/s12291-017-0711-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Yamagiwa S, Kamimura H, Takamura M, Aoyagi Y. Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol 2014; 20(10): 2606-2612 [PMID: 24627596 DOI: 10.3748/wjg.v20.i10.2606] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
17 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
18 Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us? World J Gastroenterol 2010; 16(29): 3616-3629 [PMID: 20677333 DOI: 10.3748/wjg.v16.i29.3616] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
19 Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 2013;12:421-5. [PMID: 22951216 DOI: 10.1016/j.autrev.2012.08.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
20 Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011;20:191-205. [PMID: 21303836 DOI: 10.1177/0961203310397082] [Cited by in Crossref: 106] [Cited by in F6Publishing: 85] [Article Influence: 9.6] [Reference Citation Analysis]
21 Melayah S, Kallala O, Ben Ahmed M, Fodha I, Yacoub Jemni S, Ghedira I, Mankaï A. IgA anti-beta-2 glycoprotein I antibodies in chronic hepatitis C. Arab Journal of Gastroenterology 2022. [DOI: 10.1016/j.ajg.2021.12.003] [Reference Citation Analysis]
22 Li X, Xu H, Gao P. Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center. Med Sci Monit 2020;26:e927946. [PMID: 33180750 DOI: 10.12659/MSM.927946] [Reference Citation Analysis]
23 Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, Dalekos GN. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471-479. [PMID: 23777462 DOI: 10.3109/08916934.2013.801461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
24 Zachou K, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, Dalekos GN. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. Eur J Intern Med. 2017;38:83-88. [PMID: 28100410 DOI: 10.1016/j.ejim.2017.01.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
25 Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limón P, Martínez-Martínez LA, Jatwani S, Jajoria P, Seif A, Alarcón GS, Papalardo E, Liu J, Vilá LM, McGwin G Jr, McNearney TA, Maganti R, Sunkureddi P, Parekh T, Tarantino M, Akhter E, Fang H, Gonzalez EB, Binder WR, Norman GL, Shums Z, Teodorescu M, Reveille JD, Petri M, Pierangeli SS. Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013;65:3186-93. [PMID: 23983008 DOI: 10.1002/art.38131] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
26 Mankaï A, Manoubi W, Ghozzi M, Melayah S, Sakly W, Ghedira I. High frequency of antiphospholipid antibodies in primary biliary cirrhosis. J Clin Lab Anal 2015;29:32-6. [PMID: 24687920 DOI: 10.1002/jcla.21723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Hua R, Wu H, Zhang XW, Sun YW. Probable catastrophic antiphospholipid syndrome complicated with primary sclerosing cholangitis: Probable CAPS with PSC after ERCP. Journal of Digestive Diseases 2012;13:601-3. [DOI: 10.1111/j.1751-2980.2012.00614.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Hood DB, Snyder KR, Buckner TR, Hurley BL, Pitts KR, Lopez LR. Differential assay reactivity of immunglobulin A anti-ß2 glycoprotein I antibodies: implications for the clinical interpretation of antiphospholipid antibody testing. Eur J Rheumatol 2015;2:135-8. [PMID: 27708950 DOI: 10.5152/eurjrheum.2015.0012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis 2012;2012:391567. [PMID: 23150824 DOI: 10.1155/2012/391567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]